Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Basic Trial Information
|Phase II||Treatment||Closed||1 to 17||Pharmaceutical / Industry||CA180-372|
2011-001123-20, AALL1122, NCT01460160
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL)
- Age >1 year and < less than 18 years old
- Induction chemotherapy ≤ 14 days according to institutional standard of care
- Adequate liver, renal and cardiac function
- Prior treatment with a Oncogene fusion protein (BCR-ABL) inhibitor
- Extramedullary involvement of the testicles
- Active systemic bacterial, fungal or viral infection
- Down syndrome
Trial Contact Information
Trial Lead Organizations/Sponsors
Bristol-Myers Squibb Company - New York
- Children's Oncology Group
- EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01460160
ClinicalTrials.gov processed this data on May 20, 2015
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.